These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10908521)

  • 1. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2000; (3):CD002025. PubMed ID: 10908521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Minozzi S; Ferroni E; Ali R; Ferri M
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD003409. PubMed ID: 23450540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid dependence treatment: options in pharmacotherapy.
    Stotts AL; Dodrill CL; Kosten TR
    Expert Opin Pharmacother; 2009 Aug; 10(11):1727-40. PubMed ID: 19538000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving temporal efficiency of outpatient buprenorphine induction.
    Gunderson EW; Levin FR; Rombone MM; Vosburg SK; Kleber HD
    Am J Addict; 2011; 20(5):397-404. PubMed ID: 21838837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study.
    Jones BLH; Geier M; Neuhaus J; Coffin PO; Snyder HR; Soran CS; Knight KR; Suen LW
    Harm Reduct J; 2024 Apr; 21(1):80. PubMed ID: 38594721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing Opioid Withdrawal Experiences and Consequences Among a Community Sample of People Who Use Opioids.
    Simpson KA; Bolshakova M; Kirkpatrick MG; Davis JP; Cho J; Barrington-Trimis J; Kral AH; Bluthenthal RN
    Subst Use Misuse; 2024; 59(6):886-894. PubMed ID: 38287506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.
    Dunn KE; Huhn AS; Bergeria CL; Gipson CD; Weerts EM
    J Pharmacol Exp Ther; 2019 Nov; 371(2):422-452. PubMed ID: 31391211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically meaningful individual differences in opioid withdrawal expression.
    Ware OD; Dunn KE
    Exp Clin Psychopharmacol; 2023 Dec; 31(6):1005-1009. PubMed ID: 37166910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing Opioid Use Disorder During and After Acute Hospitalization: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings.
    Noska A; Mohan A; Wakeman S; Rich J; Boutwell A
    J Addict Behav Ther Rehabil; 2015; 4(2):. PubMed ID: 26258153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing preclinical withdrawal syndrome symptomatology following heroin self-administration in male and female rats.
    Gipson CD; Dunn KE; Bull A; Ulangkaya H; Hossain A
    Exp Clin Psychopharmacol; 2021 Dec; 29(6):636-649. PubMed ID: 32297787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids.
    Kang JH; Lee KH; Huh SJ; Shin SH; Kim IH; Hwang IG; Koo DH; Lee D; Koh SJ; Seo S; Lee GJ; Chun SH; Ji JH; Oh SY; Choi JW; Go SI
    Oncologist; 2024 Jul; ():. PubMed ID: 39028339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Buprenorphine Initiation: A Scoping Review.
    Wong S; Fabiano N; Webber D; Kleinman RA
    J Addict Med; 2024 May; ():. PubMed ID: 38757944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal?
    Stern SJ; D'Orazio JL; Work BD; Calcaterra SL; Thakrar AP
    J Hosp Med; 2024 Apr; 19(4):339-343. PubMed ID: 38030816
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of dropout from inpatient opioid detoxification with buprenorphine: a chart review.
    Hakansson A; Hallén E
    J Addict; 2014; 2014():965267. PubMed ID: 25530903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer approaches to opioid detoxification.
    Sarkar S; Mattoo SK
    Ind Psychiatry J; 2012 Jul; 21(2):163-7. PubMed ID: 24250054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
    Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
    Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2002; (2):CD002025. PubMed ID: 12076434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study.
    Tamaskar R; Parran TV; Heggi A; Brateanu A; Rabb M; Yu J
    J Addict Dis; 2003; 22(4):5-12. PubMed ID: 14723474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997-2007.
    Zamparutti G; Schifano F; Corkery JM; Oyefeso A; Ghodse AH
    Br J Clin Pharmacol; 2011 Aug; 72(2):330-7. PubMed ID: 21235617
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.